The clinical pipeline of antibody–drug conjugates (ADCs) has dramatically changed since 2013, as the rapid technological advances made in the preclinical space during the early part of the decade have begun to mature into clinical-stage projects.

Iterative but meaningful improvements in ADC technology will continue as the clinical–preclinical–clinical feedback loop focuses heavily on approaches for reducing off-target toxicities and improving patient outcomes through changes in both ADC composition and clinical trial study design.

Another major focus in both clinical and preclinical arenas will be investigating combination therapies, with particular attention on how ADCs can complement immunooncology approaches. Expanded use of ADCs beyond oncology indications is also anticipated.